Charles Schwab Investment Management Inc. Takes Position in Atyr PHARMA INC (NASDAQ:ATYR)

Charles Schwab Investment Management Inc. bought a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 39,689 shares of the company’s stock, valued at approximately $144,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. D.A. Davidson & CO. acquired a new position in shares of Atyr PHARMA during the fourth quarter valued at about $141,000. JPMorgan Chase & Co. increased its position in Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after buying an additional 10,754 shares in the last quarter. Alterna Wealth Management Inc. acquired a new position in Atyr PHARMA during the 4th quarter worth approximately $36,000. Finally, Kingswood Wealth Advisors LLC acquired a new position in Atyr PHARMA during the 4th quarter worth approximately $170,000. 61.72% of the stock is owned by institutional investors.

Atyr PHARMA Trading Down 4.6 %

NASDAQ ATYR opened at $2.88 on Wednesday. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The business has a fifty day simple moving average of $3.62 and a 200 day simple moving average of $3.21. Atyr PHARMA INC has a 12 month low of $1.42 and a 12 month high of $4.66. The firm has a market capitalization of $255.91 million, a P/E ratio of -3.06 and a beta of 0.98.

Atyr PHARMA (NASDAQ:ATYR) last announced its earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, analysts predict that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ATYR shares. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a research report on Friday, March 14th. Cantor Fitzgerald assumed coverage on shares of Atyr PHARMA in a report on Monday, January 6th. They set an “overweight” rating on the stock. Finally, Leerink Partners started coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective for the company. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Atyr PHARMA has a consensus rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.